Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 110)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 14.05.24 16:44:05 von
neuester Beitrag 14.05.24 16:44:05 von
Beiträge: 23.084
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 1.471
Gesamt: 1.247.673
Gesamt: 1.247.673
Aktive User: 3
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
12,872
EUR
+5,96 %
+0,724 EUR
Letzter Kurs 16:59:21 Tradegate
Neuigkeiten
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 12:52 Uhr · wallstreetONLINE Redaktion |
13:03 Uhr · Felix Haupt Anzeige |
05:10 Uhr · inv3st.de Anzeige |
13.05.24 · Der Aktionär TV  |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein!Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6230 | +23,86 | |
| 2,2095 | +23,17 | |
| 0,8200 | +18,84 | |
| 0,9275 | +17,78 | |
| 2,4700 | +17,62 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,1200 | -18,64 | |
| 0,5350 | -20,15 | |
| 0,9900 | -27,21 | |
| 2,9600 | -28,16 | |
| 0,6162 | -56,61 |
Beitrag zu dieser Diskussion schreiben
Feedback
COVID? Was zur Hölle ist das?
https://www.foxbusiness.com/fox-news-travel/united-exec-covi…
https://www.foxbusiness.com/fox-news-travel/united-exec-covi…
Antwort auf Beitrag Nr.: 75.207.356 von rexe05351 am 02.02.24 11:56:01Der war gut 
Antwort auf Beitrag Nr.: 75.207.011 von Nokery am 02.02.24 11:02:48Lass uns doch bitte nicht über Fakten reden, sondern lieber über Berichte die 1000% Kurssprung vorhersagen
nochmal einige Aussagen des Q3/23 Berichts zur Einordnung der Werbetrommelrührerkommentare:
Verkauf von Matrix M
"Third quarter 2023 royalty and other revenue includes $12 million in Matrix-M sales to our collaboration partner in support of launch preparations for the R21/Matrix-M malaria vaccine."
Die Q4/23-Zahlen werden lt. Q3/22 Bericht mies...
Die FY2023 Guidance hat mal kurzerhand das Q1/24 in die Guidance für FY2023 optisch inkludiert:
" 
NEWS & MEDIA
Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
November 9, 2023
Received authorization from the U.S. FDA and approval from the European Commission for the Company's updated COVID-19 vaccine, and launched the only protein-based non-mRNA vaccine option
Secured broad access to Novavax's COVID-19 vaccine in the U.S.
R21/Matrix-M malaria vaccine received recommendation from WHO, resulting in initial sales of Matrix-M for launch
Anticipate Phase 3 COVID-19-Influenza Combination vaccine trial to commence in 2024, with potential for accelerated approval and launch in 2026
Expect to deliver total revenue at low end of guidance range for season, when accounting for some revenue shifting into first quarter 2024
Prepared to initiate additional cost reduction program, targeting over $300 million in 2024 to align company scope and structure with future COVID-19 market opportunity
Company to host conference call today at 8:30 a.m. ET
GAITHERSBURG, Md., Nov. 9, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.
"We are proud of the progress we made over the last quarter to deliver the only protein-based non-mRNA vaccine option in the U.S. and have worked to provide broad access across retail pharmacies and healthcare offices," said John C. Jacobs, President and Chief Executive Officer, Novavax. "With the delayed start of respiratory vaccinations, we believe we have yet to reach the midpoint of the vaccination season and, with early and encouraging signs of demand for our vaccine, we believe there remains opportunity to deliver doses and grow our share. This reinforces our belief that the long-term COVID-19 market represents a sustainable opportunity for Novavax in the years to come."
"As previously stated, one of our key objectives is to strengthen the financial stability of the company. We are currently exceeding the targeted reductions announced earlier in the year and did so while launching our updated vaccine. To more efficiently scale our business, we are prepared to initiate additional cost reductions to further reduce expenses in 2024 by over $300 million, while continuing to maintain our key capabilities and our ability to bring forward a combination vaccine."
Third Quarter 2023 and Recent Highlights
During the third quarter, Novavax continued to make progress on its three key priorities for 2023.
Priority #1: Deliver an Updated COVID-19 Vaccine for the Upcoming 2023 Fall Vaccination Season
U.S. Market: Novavax received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in October for its updated COVID-19 vaccine and is executing its commercial strategy to maximize access for consumers who want a protein-based non-mRNA vaccine option.
Expect U.S. 2023-2024 season COVID-19 vaccine demand of between 30 and 50 million doses, with potential for significant November and December vaccinations given current trends and later start as compared to 2022
Secured broad access to the Company's updated vaccine through major pharmacies, clinics and government programs
Novavax's vaccine is available at approximately 14,000 pharmacy locations, including Costco, CVS Pharmacy, Giant, Publix, Rite Aid and Stop & Shop
Global Markets: Received approval in Europe for the Company's updated COVID-19 vaccine in individuals aged 12 and older
Advanced regulatory filings against existing APAs for Australia, Canada, New Zealand, Singapore and Taiwan
Priority #2: Reduce Rate of Spend, Manage Cash Flow and Evolve Scale and Structure
Novavax has made significant progress on its commitment to improve its financial position while maintaining the capabilities to support long-term value creation.
Reduced current liabilities by $128 million during the third quarter of 2023 and by approximately $1 billion as of September 30, 2023
Reduced year-to-date operating expenses through the third quarter of 2023 by $950 million or 47%, as compared to 2022
On track to exceed the previously announced global restructuring and cost reduction plan for 2023 by over $100 million for combined Research and Development (R&D) and Selling, General, and Administrative (SG&A) expenses
Prepared to initiate additional cost reductions to further reshape the size and scope of global operations beyond previously stated cost reduction targets by over $300 million
Priority #3: Leverage Technology Platform, Capabilities, and Portfolio of Assets to Drive Additional Value Beyond Nuvaxovid™
Novavax remains focused on leveraging its technology platform to drive long-term growth and protect global health.
Expect to initiate a pivotal Phase 3 trial for COVID-19-Influenza Combination (CIC) vaccine candidate in the second half of 2024, with potential for accelerated approval and launch as early as 2026
Advanced partnerships with Matrix-M adjuvant technology
R21/Matrix-M vaccine received recommendation from the World Health Organization; launch expected in 2024
Third Quarter 2023 Financial Results
Total revenue for the third quarter of 2023 was $187 million, compared to $735 million in the same period in 2022. Third quarter 2023 grant revenue of $165 million benefited from milestone achievements related to U.S. market preparedness and progress on clinical projects. Third quarter 2023 royalty and other revenue includes $12 million in Matrix-M sales to our collaboration partner in support of launch preparations for the R21/Matrix-M malaria vaccine.
Cost of sales for the third quarter of 2023 were $99 million, compared to $435 million in the same period in 2022. Third quarter 2023 cost of sales includes $82 million related to excess, obsolete or expired inventory and losses on firm purchase commitments as compared to $249 million in the same period in 2022. Third quarter 2023 cost of sales also includes a $22 million benefit related to certain negotiated reductions to previously recognized firm purchase commitments.
R&D expenses for the third quarter of 2023 were $106 million, compared to $304 million in the same period in 2022. The decrease was primarily due to reduction in clinical and manufacturing spend and a $58 million benefit associated with the negotiated settlement of manufacturing liabilities recorded in the third quarter of 2023.
SG&A expenses for the third quarter of 2023 were $107 million, compared to $123 million for the same period in 2022. The decrease was primarily due to certain cost containment measures to reduce operating spend
Net loss for the third quarter 2023 was $131 million, compared to a net loss of $169 million in the same period in 2022.
Cash, cash equivalents and restricted cash were $666 million as of September 30, 2023, compared to $518 million as of June 30, 2023, and $1.3 billion as of December 31, 2022. Through sales of Novavax common stock pursuant to at-the-market offerings during the third quarter of 2023, Novavax raised net proceeds of $143 million.
Financial Framework
Novavax is updating its Full Year 2023 guidance and providing First Quarter 2024 total revenue guidance:
For updated total revenue guidance, we have included combined FY 2023 and Q1 2024 total revenue to reflect the full delivery timing and revenue recognition of sales associated with the 2023-2024 vaccination season. Consistent with 2023, we originally expected no product sales revenue in the first quarter of 2024. Due to the delayed start to and expectation for a longer season in the U.S., we expect some portion of revenue recognition will extend into the first quarter of 2024."
https://ir.novavax.com/press-releases/2023-11-09-Novavax-Rep…
Verkauf von Matrix M
"Third quarter 2023 royalty and other revenue includes $12 million in Matrix-M sales to our collaboration partner in support of launch preparations for the R21/Matrix-M malaria vaccine."
Die Q4/23-Zahlen werden lt. Q3/22 Bericht mies...
Die FY2023 Guidance hat mal kurzerhand das Q1/24 in die Guidance für FY2023 optisch inkludiert:
" 
NEWS & MEDIA
Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
November 9, 2023
Received authorization from the U.S. FDA and approval from the European Commission for the Company's updated COVID-19 vaccine, and launched the only protein-based non-mRNA vaccine option
Secured broad access to Novavax's COVID-19 vaccine in the U.S.
R21/Matrix-M malaria vaccine received recommendation from WHO, resulting in initial sales of Matrix-M for launch
Anticipate Phase 3 COVID-19-Influenza Combination vaccine trial to commence in 2024, with potential for accelerated approval and launch in 2026
Expect to deliver total revenue at low end of guidance range for season, when accounting for some revenue shifting into first quarter 2024
Prepared to initiate additional cost reduction program, targeting over $300 million in 2024 to align company scope and structure with future COVID-19 market opportunity
Company to host conference call today at 8:30 a.m. ET
GAITHERSBURG, Md., Nov. 9, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.
"We are proud of the progress we made over the last quarter to deliver the only protein-based non-mRNA vaccine option in the U.S. and have worked to provide broad access across retail pharmacies and healthcare offices," said John C. Jacobs, President and Chief Executive Officer, Novavax. "With the delayed start of respiratory vaccinations, we believe we have yet to reach the midpoint of the vaccination season and, with early and encouraging signs of demand for our vaccine, we believe there remains opportunity to deliver doses and grow our share. This reinforces our belief that the long-term COVID-19 market represents a sustainable opportunity for Novavax in the years to come."
"As previously stated, one of our key objectives is to strengthen the financial stability of the company. We are currently exceeding the targeted reductions announced earlier in the year and did so while launching our updated vaccine. To more efficiently scale our business, we are prepared to initiate additional cost reductions to further reduce expenses in 2024 by over $300 million, while continuing to maintain our key capabilities and our ability to bring forward a combination vaccine."
Third Quarter 2023 and Recent Highlights
During the third quarter, Novavax continued to make progress on its three key priorities for 2023.
Priority #1: Deliver an Updated COVID-19 Vaccine for the Upcoming 2023 Fall Vaccination Season
U.S. Market: Novavax received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in October for its updated COVID-19 vaccine and is executing its commercial strategy to maximize access for consumers who want a protein-based non-mRNA vaccine option.
Expect U.S. 2023-2024 season COVID-19 vaccine demand of between 30 and 50 million doses, with potential for significant November and December vaccinations given current trends and later start as compared to 2022
Secured broad access to the Company's updated vaccine through major pharmacies, clinics and government programs
Novavax's vaccine is available at approximately 14,000 pharmacy locations, including Costco, CVS Pharmacy, Giant, Publix, Rite Aid and Stop & Shop
Global Markets: Received approval in Europe for the Company's updated COVID-19 vaccine in individuals aged 12 and older
Advanced regulatory filings against existing APAs for Australia, Canada, New Zealand, Singapore and Taiwan
Priority #2: Reduce Rate of Spend, Manage Cash Flow and Evolve Scale and Structure
Novavax has made significant progress on its commitment to improve its financial position while maintaining the capabilities to support long-term value creation.
Reduced current liabilities by $128 million during the third quarter of 2023 and by approximately $1 billion as of September 30, 2023
Reduced year-to-date operating expenses through the third quarter of 2023 by $950 million or 47%, as compared to 2022
On track to exceed the previously announced global restructuring and cost reduction plan for 2023 by over $100 million for combined Research and Development (R&D) and Selling, General, and Administrative (SG&A) expenses
Prepared to initiate additional cost reductions to further reshape the size and scope of global operations beyond previously stated cost reduction targets by over $300 million
Priority #3: Leverage Technology Platform, Capabilities, and Portfolio of Assets to Drive Additional Value Beyond Nuvaxovid™
Novavax remains focused on leveraging its technology platform to drive long-term growth and protect global health.
Expect to initiate a pivotal Phase 3 trial for COVID-19-Influenza Combination (CIC) vaccine candidate in the second half of 2024, with potential for accelerated approval and launch as early as 2026
Advanced partnerships with Matrix-M adjuvant technology
R21/Matrix-M vaccine received recommendation from the World Health Organization; launch expected in 2024
Third Quarter 2023 Financial Results
Total revenue for the third quarter of 2023 was $187 million, compared to $735 million in the same period in 2022. Third quarter 2023 grant revenue of $165 million benefited from milestone achievements related to U.S. market preparedness and progress on clinical projects. Third quarter 2023 royalty and other revenue includes $12 million in Matrix-M sales to our collaboration partner in support of launch preparations for the R21/Matrix-M malaria vaccine.
Cost of sales for the third quarter of 2023 were $99 million, compared to $435 million in the same period in 2022. Third quarter 2023 cost of sales includes $82 million related to excess, obsolete or expired inventory and losses on firm purchase commitments as compared to $249 million in the same period in 2022. Third quarter 2023 cost of sales also includes a $22 million benefit related to certain negotiated reductions to previously recognized firm purchase commitments.
R&D expenses for the third quarter of 2023 were $106 million, compared to $304 million in the same period in 2022. The decrease was primarily due to reduction in clinical and manufacturing spend and a $58 million benefit associated with the negotiated settlement of manufacturing liabilities recorded in the third quarter of 2023.
SG&A expenses for the third quarter of 2023 were $107 million, compared to $123 million for the same period in 2022. The decrease was primarily due to certain cost containment measures to reduce operating spend
Net loss for the third quarter 2023 was $131 million, compared to a net loss of $169 million in the same period in 2022.
Cash, cash equivalents and restricted cash were $666 million as of September 30, 2023, compared to $518 million as of June 30, 2023, and $1.3 billion as of December 31, 2022. Through sales of Novavax common stock pursuant to at-the-market offerings during the third quarter of 2023, Novavax raised net proceeds of $143 million.
Financial Framework
Novavax is updating its Full Year 2023 guidance and providing First Quarter 2024 total revenue guidance:
For updated total revenue guidance, we have included combined FY 2023 and Q1 2024 total revenue to reflect the full delivery timing and revenue recognition of sales associated with the 2023-2024 vaccination season. Consistent with 2023, we originally expected no product sales revenue in the first quarter of 2024. Due to the delayed start to and expectation for a longer season in the U.S., we expect some portion of revenue recognition will extend into the first quarter of 2024."
https://ir.novavax.com/press-releases/2023-11-09-Novavax-Rep…
Antwort auf Beitrag Nr.: 75.206.285 von BTC123 am 02.02.24 09:33:23
"Everyone 6 months and older should stay up-to-date with the COVID-19 vaccine."
Was soll denn so eine unsinnige und völlig unseriöse Empfehlung? Kommt offenbar direkt von einem Impfhersteller oder Jemand, der auf der Payroll eines solchen steht....les doch bitte vorher, was du hier postest!
Zitat von BTC123: The Importance of Updated COVID-19 Vaccination: Protecting Against Variants Including JN.1
By
Anthony Raphael
3 min read
Published Feb 1, 2024 at 3:46 pm EST | Updated Feb 1, 2024 at 3:46 pm EST
Understanding the Importance of Updated COVID-19 Vaccination
https://medriva.com/covid-19/the-importance-of-updated-covid…
"Everyone 6 months and older should stay up-to-date with the COVID-19 vaccine."
Was soll denn so eine unsinnige und völlig unseriöse Empfehlung? Kommt offenbar direkt von einem Impfhersteller oder Jemand, der auf der Payroll eines solchen steht....les doch bitte vorher, was du hier postest!
Trading Spotlight
Zweiter Malaria-Impfstoff bietet laut Studienergebnissen hohen Schutz
2. Feb. 202400:30 MEZ
Ein von der Universität Oxford und dem Serum Institute of India entwickelter Malaria-Impfstoff verhinderte im ersten Jahr nach der Impfung rund drei Viertel der symptomatischen Malariafälle bei Kleinkindern, wie die Ergebnisse einer groß angelegten Studie am Donnerstag zeigten.
Der Impfstoff, der bereits von den Aufsichtsbehörden in drei westafrikanischen Ländern (link) und der Weltgesundheitsorganisation (link) zugelassen wurde, ist der zweite, der in diesem Jahr auf den Markt kommt.
Der erste Impfstoff wurde Anfang dieses Monats in Kamerun (link) auf den
https://de.tradingview.com/news/reuters.com,2024:newsml_L8N3…
2. Feb. 202400:30 MEZ
Ein von der Universität Oxford und dem Serum Institute of India entwickelter Malaria-Impfstoff verhinderte im ersten Jahr nach der Impfung rund drei Viertel der symptomatischen Malariafälle bei Kleinkindern, wie die Ergebnisse einer groß angelegten Studie am Donnerstag zeigten.
Der Impfstoff, der bereits von den Aufsichtsbehörden in drei westafrikanischen Ländern (link) und der Weltgesundheitsorganisation (link) zugelassen wurde, ist der zweite, der in diesem Jahr auf den Markt kommt.
Der erste Impfstoff wurde Anfang dieses Monats in Kamerun (link) auf den
https://de.tradingview.com/news/reuters.com,2024:newsml_L8N3…
The Importance of Updated COVID-19 Vaccination: Protecting Against Variants Including JN.1
By
Anthony Raphael
3 min read
Published Feb 1, 2024 at 3:46 pm EST | Updated Feb 1, 2024 at 3:46 pm EST
Understanding the Importance of Updated COVID-19 Vaccination
https://medriva.com/covid-19/the-importance-of-updated-covid…
By
Anthony Raphael
3 min read
Published Feb 1, 2024 at 3:46 pm EST | Updated Feb 1, 2024 at 3:46 pm EST
Understanding the Importance of Updated COVID-19 Vaccination
https://medriva.com/covid-19/the-importance-of-updated-covid…
02 FEB 2024 11:07 AM AEDTShare
Phase 3 Trial Confirms High Efficacy of R21/Matrix-M Malaria Vaccine
Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5-17-month age group over the first year
To date 25 million doses manufactured and ready for roll-out by The Serum Institute of India (SII) in the next three to four months
Phase 3 Trial data results of The R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax's Matrix-M adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. The R21/Matrix-M vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M could reach the WHO-specified target of 75% efficacy in African children. Recent WHO endorsement will lead to the initial rollout of R21/Matrix-M in the coming months. The new results are published in The Lancet today.
The trial investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali....
https://www.miragenews.com/phase-3-trial-confirms-high-effic…
Phase 3 Trial Confirms High Efficacy of R21/Matrix-M Malaria Vaccine
Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5-17-month age group over the first year
To date 25 million doses manufactured and ready for roll-out by The Serum Institute of India (SII) in the next three to four months
Phase 3 Trial data results of The R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax's Matrix-M adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. The R21/Matrix-M vaccine was designed in 2011 as a potential improvement on the RTS, S/AS01 malaria vaccine designed in the 1980s. A phase II trial in Burkina Faso, reporting in 2021, was the first to show that R21/Matrix-M could reach the WHO-specified target of 75% efficacy in African children. Recent WHO endorsement will lead to the initial rollout of R21/Matrix-M in the coming months. The new results are published in The Lancet today.
The trial investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali....
https://www.miragenews.com/phase-3-trial-confirms-high-effic…
Antwort auf Beitrag Nr.: 75.205.934 von rexe05351 am 02.02.24 08:52:00Leidest Du irgendwie unter Verfolgungswahn?
Weißt DU überhaupt was naked short selling ist?
Weißt DU überhaupt was naked short selling ist?
Antwort auf Beitrag Nr.: 75.205.745 von BTC123 am 02.02.24 08:18:46Nett das du für deine gespaltene Persönlichkeit
antwortest..
Naked Short selling, verstehst du erst recht nicht! Poste schön deine Artikel, dann fällt nicht so auf das du immer nur die Überschriften verstehst
antwortest..
Naked Short selling, verstehst du erst recht nicht! Poste schön deine Artikel, dann fällt nicht so auf das du immer nur die Überschriften verstehst
Durchsuchen
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 12:52 Uhr · wallstreetONLINE Redaktion · Sanofi |
05:10 Uhr · inv3st.de · BayerAnzeige |
10.05.24 · dpa-AFX · McDonald's |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Enel |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Sanofi |
10.05.24 · Sharedeals · Novavax |